

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

February 11, 2026

To The Manager, Listing Department National Stock Exchange of India Limited Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department BSE Limited Phiroze Jeejabhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
--	---

Sub.: Outcome of Board Meeting held today i.e. Wednesday, February 11, 2026 - Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) as amended from time to time.

Dear Sir/ Ma’am,

With reference to the intimation of Board meeting submitted on February 06, 2026, we would like to inform you that the Board of Directors of the Company, at its meeting held today i.e. Wednesday, February 11, 2026, has inter-alia;

1. UNAUDITED FINANCIAL RESULTS

On review and recommendation of Audit Committee of the Company the Board approved Unaudited Standalone and Consolidated Financial Results for the Third quarter and Nine months ended on December on 31, 2025.

Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we enclose herewith the Unaudited Standalone and Consolidated Financial Results of the Company for the Third quarter and Nine months ended on December 31, 2025, along with the Limited Review Reports with Unmodified Opinion issued by M/s. BSR & Co. LLP, the Statutory Auditors.

2. APPOINTMENT OF KEY MANAGERIAL PERSONNEL

On the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company, appointed Mr. Paritosh Trivedi (A63623) as Company Secretary, Compliance Officer and Nodal Officer of the Company with effect from February 11, 2026.

Details pertaining of SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30, 2026 is enclosed herewith.

The Board Meeting commenced at 05:00 P.M. and concluded at 06:22 P.M.

This is for your information and records.

For Concord Biotech Limited

Mr. Sudhir Vaid
Chairman & Managing Director
(DIN: 00055967)
Encl : As above

B S R & Co. LLP

Chartered Accountants

903 Commerce House V
Near Vodafone House, Prahaladnagar
Corporate Road, Ahmedabad 380 051
India Telephone: +91 (79) 7145 0001
Fax: +91 (79) 7145 0050

Limited Review Report on unaudited standalone financial results of Concord Biotech Limited for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Concord Biotech Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Concord Biotech Limited (hereinafter referred to as "the Company") for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.: 101248W/W-100022



Rupen Shah

Partner

Ahmedabad

11 February 2026

Membership No.: 116240

UDIN: 26116240CWJVEE9850

CONCORD BIOTECH LIMITED


B-1601-1602, B-Wing, Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
E-mail : complianceofficer@concordbiotech.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

(Rs. In lakhs except per share data)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-25 (Unaudited)	30-Sept-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Dec-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Mar-25 (Audited)
1	Income						
a	Revenue from operations	27,813.39	24,705.75	24,422.02	72,917.90	77,020.31	1,20,008.69
b	Other income	1,008.22	1,342.91	1,472.94	3,718.89	3,506.27	4,444.67
	Total Income	28,821.61	26,048.66	25,894.96	76,636.79	80,526.58	1,24,453.36
2	Expenses						
a	Cost of materials consumed	6,659.28	5,730.43	6,095.60	18,380.69	18,404.38	26,431.26
b	Purchase of stock-in-trade	2,006.71	1,364.51	1,219.00	4,655.85	4,566.87	5,598.72
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,049.51)	(2,193.31)	(2,074.80)	(7,007.92)	(5,269.69)	(1,478.67)
d	Employee benefits expense	4,408.72	4,318.27	3,464.05	12,516.73	9,996.79	13,893.36
e	Finance costs	5.84	5.86	9.74	17.56	43.38	52.93
f	Depreciation and amortisation expense	1,867.25	1,838.96	1,326.40	5,483.84	3,975.69	5,437.35
g	Other expenses						
	Power and fuel	2,843.66	2,852.80	2,644.10	8,643.96	8,289.29	11,223.02
	Others	3,722.41	3,579.39	3,278.87	10,313.12	9,441.79	13,707.85
	Total expenses	19,464.36	17,496.91	15,962.96	53,003.83	49,448.50	74,865.82
3	Profit before exceptional items and tax (1-2)	9,357.25	8,551.75	9,932.00	23,632.96	31,078.08	49,587.54
4	Exceptional items:						
	Statutory impact of new labour codes (refer note 3)	327.54	-	-	327.54	-	-
5	Profit before tax (3-4)	9,029.71	8,551.75	9,932.00	23,305.42	31,078.08	49,587.54
6	Tax expenses:						
a	Current tax	2,156.83	2,199.60	2,369.23	5,764.28	7,714.61	11,896.14
b	Deferred tax	94.61	62.52	153.89	216.68	260.79	394.96
	Total tax expenses	2,251.44	2,262.12	2,523.12	5,980.96	7,975.40	12,291.10
7	Profit after tax for the period/year (5-6)	6,778.27	6,289.63	7,408.88	17,324.46	23,102.69	37,296.44
8	Other comprehensive income / (loss) (net of tax)						
	Items that will not be reclassified to profit or loss						
a	Re-measurement gain/ (loss) on defined benefit plans	(63.44)	2.02	(70.19)	(93.50)	(78.35)	(56.98)
b	Income tax relating to re-measurement gain/ (loss) on defined benefit plans	15.97	(0.51)	17.67	23.53	19.72	14.34
c	Fair value changes on equity investments through OCI	2,748.13	2,598.15	(123.60)	5,001.67	(123.60)	854.62
d	Income tax relating to fair value changes on equity investments through OCI	(392.98)	(408.99)	31.11	(715.24)	31.11	(215.09)
	Other comprehensive income / (loss) for the period/year	2,307.68	2,190.67	(145.01)	4,216.46	(151.12)	596.89
9	Total comprehensive income for the period/year (7+8)	9,085.95	8,480.30	7,263.87	21,540.92	22,951.56	37,893.33
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
11	Other equity						1,80,218.46
12	Earnings per share						
	Basic and diluted (In Rs.) (not annualised)	6.48	6.01	7.08	16.56	22.08	35.65

Refer notes to the unaudited standalone financial results



[Handwritten signature]



CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
E-mail : complianceofficer@concordbiotech.com

Notes to the statement of unaudited standalone financial results for the quarter and nine months ended December 31, 2025 :

- 1 The above standalone financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on February 11, 2026. The Statutory Auditors of the company have carried out a limited review of the said results.
- 2 The Company is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment".
- 3 On 21 November 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour and Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from these changes. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the Company has recognised an incremental liability of ₹ 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the standalone results for the quarter and nine months ended 31 December 2025. The Company continues to monitor the notification of final Central/State rules and related clarifications and will evaluate and account for any additional impact in the period in which such rules are notified or clarifications issued.
- 4 The above standalone financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI").

For and on behalf of board of directors of
Concord Biotech Limited



Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

Place: Ahmedabad
Date: February 11, 2026




Limited Review Report on unaudited consolidated financial results of Concord Biotech Limited for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Concord Biotech Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Concord Biotech Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of the net profit after tax and total comprehensive income of its joint venture for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement:
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Limited Review Report (Continued)

Concord Biotech Limited

6. The Statement includes the interim financial information of two subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 22.95 Lakhs and Rs. 22.95 Lakhs, total net (loss) after tax (before consolidation adjustments) of Rs. (345.54) lakhs and Rs. (558.01) lakhs and total comprehensive (loss) (before consolidation adjustments) of Rs. (345.54) lakhs and Rs. (558.01) lakhs, for the quarter ended 31 December 2025 and for the period from 1 April 2025 to 31 December 2025 respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax (before consolidation adjustments) of Rs. 3.56 Lakhs and Rs. 46.58 Lakhs and total comprehensive income (before consolidation adjustments) of Rs. 3.56 Lakhs and Rs. 46.58 Lakhs, for the quarter ended 31 December 2025 and for the period from 1 April 2025 to 31 December 2025 respectively as considered in the Statement, in respect of one joint venture, based on its interim financial information which has not been reviewed. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Rupen Shah

Partner

Ahmedabad

11 February 2026

Membership No.: 116240

UDIN:26116240QSRFWK5835

Limited Review Report (Continued)

Concord Biotech Limited

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Concord Biotech Limited	Parent Company
2	Concord Lifegen Limited	Wholly owned subsidiary
3	Stellon Biotech Inc.	Subsidiary
4	Concord Biotech Japan K.K.	Joint Venture



CONCORD BIOTECH LIMITED


B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
E-mail : complianceofficer@concordbiotech.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2025

(Rs. In lakhs except per share data)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-Dec-25 (Unaudited)	30-Sep-25 (Unaudited)	31-Dec-24 (Unaudited)	31-Dec-25 (Unaudited)	31-Dec-24 (Unaudited)	
1	Income						
a	Revenue from operations	27,776.60	24,705.75	24,422.02	72,881.11	77,020.31	1,20,008.69
b	Other income	997.62	1,335.21	1,472.94	3,700.59	3,506.27	4,444.67
	Total Income	28,774.22	26,040.96	25,894.96	76,581.70	80,526.58	1,24,453.36
2	Expenses						
a	Cost of materials consumed	6,659.28	5,730.43	6,095.60	18,380.69	18,404.38	26,431.26
b	Purchase of stock-in-trade	2,044.47	1,364.51	1,219.00	4,693.61	4,566.87	5,598.72
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(2,130.27)	(2,193.31)	(2,074.80)	(7,088.68)	(5,269.69)	(1,478.67)
d	Employee benefits expense	4,678.07	4,445.55	3,464.05	12,913.36	9,996.79	13,893.36
e	Finance costs	8.15	5.91	9.74	19.92	43.38	52.93
f	Depreciation and amortisation expense	1,874.69	1,839.15	1,326.40	5,491.47	3,975.69	5,437.35
g	Other expenses						
	Power and fuel	2,843.66	2,852.80	2,644.10	8,643.96	8,289.29	11,223.02
	Others	3,783.35	3,656.66	3,278.87	10,451.33	9,441.79	13,707.85
	Total Expenses	19,761.40	17,701.70	15,962.96	53,505.66	49,448.50	74,865.82
3	Profit before exceptional items and tax (1-2)	9,012.82	8,339.26	9,932.00	23,076.04	31,078.08	49,587.54
4	Exceptional items:						
	Statutory impact of new labour codes (refer note 4)	327.54	-	-	327.54	-	-
5	Profit before tax and share of profit of joint venture (3-4)	8,685.28	8,339.26	9,932.00	22,748.50	31,078.08	49,587.54
6	Share of profit / (loss) of joint venture (net of tax)	(69.69)	229.14	183.23	308.68	22.83	(132.21)
7	Profit before tax (5+6)	8,615.59	8,568.40	10,115.23	23,057.18	31,100.91	49,455.33
8	Tax expenses:						
a	Current tax	2,156.83	2,199.60	2,369.23	5,764.28	7,714.61	11,896.14
b	Deferred tax	94.61	62.52	153.89	216.68	260.79	394.96
	Total tax expenses	2,251.44	2,262.12	2,523.12	5,980.96	7,975.40	12,291.10
9	Profit after tax for the period/year (7-8)	6,364.15	6,306.28	7,592.11	17,076.22	23,125.51	37,164.23
10	Other comprehensive income / (loss) (net of tax)						
	Items that will not be reclassified to profit or loss						
a	Re-measurement gain/ (loss) on defined benefit plans	(63.44)	2.02	(70.19)	(93.50)	(78.35)	(56.98)
b	Income tax relating to re-measurement gain/ (loss) on defined benefit plans	15.97	(0.51)	17.67	23.53	19.72	14.34
c	Fair value changes on equity investments through OCI	2,748.13	2,598.15	(123.60)	5,001.67	(123.60)	854.62
d	Income tax relating to fair value changes on equity investments through OCI	(392.98)	(408.99)	31.11	(715.24)	31.11	(215.09)
	Items that will be reclassified to profit or loss						
a	Foreign currency translation reserves	(12.95)	(5.49)	-	(18.44)	-	-
	Other comprehensive income / (loss) for the period/year	2,294.73	2,185.18	(145.01)	4,198.02	(151.12)	596.89
11	Total comprehensive income for the period/year(9+10)	8,658.88	8,491.46	7,447.10	21,274.24	22,974.39	37,761.12
12	Profit for the period attributable to:						
	Owners of the company	6,447.66	6,358.09	7,592.11	17,211.54	23,125.51	37,164.23
	Non-controlling interest	(83.51)	(51.81)	-	(135.32)	-	-
	Profit for the period	6,364.15	6,306.28	7,592.11	17,076.22	23,125.51	37,164.23
13	Other comprehensive income / (loss) for the period attributable to:						
	Owners of the company	2,297.97	2,186.55	(145.01)	4,202.63	(151.12)	596.89
	Non-controlling interest	(3.24)	(1.37)	-	(4.61)	-	-
	Other comprehensive income / (loss) for the period	2,294.73	2,185.18	(145.01)	4,198.02	(151.12)	596.89
14	Total comprehensive income for the period attributable to:						
	Owners of the company	8,745.63	8,544.65	7,447.10	21,414.17	22,974.39	37,761.12
	Non-controlling interest	(86.75)	(53.18)	-	(139.93)	-	-
	Total comprehensive income for the period	8,658.88	8,491.46	7,447.10	21,274.24	22,974.39	37,761.12
15	Paid-up equity share capital (face value of Rs. 1/- each)	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
16	Other equity						1,80,225.59
17	Earnings per share						
	Basic and diluted (In Rs.) (not annualised)	6.08	6.03	7.26	16.32	22.11	35.52

See accompanying notes to the consolidated unaudited financial results



Regd. Office & Plant : 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225 (India)
Phone : +91-2714-222604, 398200 Fax : +91-2714-222504 Website : www.concordbiotech.com

CONCORD BIOTECH LIMITED

B-1601-1602, B-Wing, Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380 015, Gujarat.


Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

E-mail : complianceofficer@concordbiotech.com

Notes to the statement of unaudited consolidated financial results for the quarter and nine months ended December 31, 2025:

- 1 The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on 11th february, 2026. The Statutory Auditors of the company have carried out a limited review of the said results.
- 2 The unaudited consolidated financial results of the Group include information of wholly owned subsidiary Concord Lifegen Limited (w.e.f 21st July 2025), subsidiary Stellon Biotech Inc. (w.e.f 1st July 2025) and joint venture Concord Biotech Japan K.K.
- 3 The Group is engaged in the business of manufacturing and trading in pharmaceutical products. The entire business is considered as a single operating segment in terms of Indian Accounting Standard (Ind AS) 108 - "Operating Segment".
- 4 On 21 November 2025, the Government of India notified four Labour Codes consolidating 29 existing labour laws. The Ministry of Labour and Employment has issued draft Central Rules and FAQs to facilitate assessment of the financial impact arising from these changes. Based on management's assessment including actuarial valuation, considering the best information available and ICAI guidance, the Company has recognised an incremental liability of ₹ 327.54 lakhs towards employee benefit obligation, primarily arising from the revised definition of wages under the New Labour Codes. Considering the event as regulatory-driven and non-recurring in nature, the impact of the same has been disclosed under exceptional items in the standalone results for the quarter and nine months ended 31 December 2025. The Company continues to monitor the notification of final Central/State rules and related clarifications and will evaluate and account for any additional impact in the period in which such rules are notified or clarifications issued.
- 5 The above consolidated financial results has been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act, 2013 read together with Companies (Indian Accounting Standards) Rules, 2015 and in accordance with the guidelines issued by the Securities and Exchange Board of India ("SEBI").

Place: Ahmedabad
Date: February 11, 2026



For and on behalf of board of directors of
Concord Biotech Limited

Sudhir Vaid
Chairman & Managing Director
DIN: 00055967

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

- A. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc. - **Not Applicable**
- B. Format for Disclosing Outstanding Default on Loans and Debt Securities — **Not Applicable, No Default**
- C. Format for Disclosure of Related Party Transactions (applicable only for half yearly filings i.e., 2nd and 4th quarter) — **Not Applicable**
- D. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - **Not Applicable**

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeval Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

APPOINTMENT OF KEY MANAGERIAL PERSONNEL:

Sl. No	Particulars Details	Particulars Details
1.	Name of the Company Secretary	Mr. Paritosh Trivedi
2.	Reason for change	Appointment
3.	Date of appointment	February 11, 2026
4.	Brief Profile	Mr. Paritosh Trivedi is an Associate Member of the Institute of Company Secretaries of India (Membership No. A63623) and a Commerce Post Graduate with around 5 years of experience in corporate compliance, governance, and secretarial functions. Skilled in regulatory compliance, statutory filings and corporate governance across diverse sectors. He has previously held Compliance roles with reputed entities in Textile, IT/ITeS and FMCG sectors.
5.	Disclosure of relationships between directors	Not related to any of the Directors of the Company.
6.	Shareholding in the company, if any	NIL